partly attributable to the overproduction of reactive oxygen species (ROS) and the disruption of oxidative stress pathways. [6] [7] [8] In response to oxidative stress, cytosolic NRF2 (nuclear factor, erythroid 2 like 2) translocates to the nucleus and binds to the antioxidant response element (ARE) in the promoter region of antioxidant genes to initiate their transcription. 9 NRF2-mediated transcription is not induced in AD neurons despite the presence of oxidative stress. 10 Both Aβ aggregation and NRF2 downregulation impair neuronal differentiation. 11 Compounds possessing antiaggregation and antioxidant properties may modify the disease course in various AD models. [12] [13] [14] [15] Licochalcone A (Lico A) is a major chalcone constituent obtained from the root of Glycyrrhiza inflata. 16 Lico A activates the NRF2-ARE pathway, thereby reducing oxidative stress and polyglutamine aggregate formation in spinocerebellar ataxia type 3 cell models. 17 In mouse RAW 264.7 macrophages, Lico A enhanced the NRF2-mediated defense mechanism against oxidative stress and cell death. 18 In addition, Lico A activated NRF2 in primary human fibroblasts and reduced oxidative stress in human skin. 19 Coumarin, a natural product found in many green plants, also exhibits antioxidant activity. 20, 21 In the APP/presenilin 1 (PS1) transgenic AD cell line, coumarin derivatives functioned as free radical scavengers to protect against H 2 O 2 -induced oxidative stress. 22 In addition, coumarin derivatives could prevent misfolded Aβ aggregation. 23 These studies have suggested that Lico A and coumarin are promising lead compounds for the synthesis of novel AD therapeutics.
In the present study, we synthesized new derivatives of Lico A and coumarin and investigated their ability to prevent Aβ aggregation and oxidation as well as promote neuroprotection by using biochemical assays and Tet-On Aβ-GFP 293/SH-SY5Y AD cells. 24 Our findings indicate that the novel chalcone-coumarin hybrid LM-031 is a potential lead candidate for the development of AD therapeutics, owing to its ability to prevent Aβ aggregation and oxidation in neuronal cells.
| MATERIAL S AND ME THODS

| Test compounds
Lico A, coumarin, and curcumin were purchased from Sigma-Aldrich, St. Louis, MO, USA. The Lico A derivatives LM-004 and LM-006 and the coumarin derivative LM-016 were synthesized according to previous reports. 25, 26 LM-026 was synthesized using the procedure reported by Mazimba et al 27 with some modifications, and LM-031 was synthesized using the procedures reported by Dube et al 28 and Tietze et al 29 with some modifications. In a cell culture medium, LM-004 and LM-031 were soluble up to 1 mmol/L, whereas LM-006, LM-016, and LM-026 were soluble up to 100 μmol/L.
| Thioflavin T binding assay
To examine the inhibition of Aβ aggregation, the thioflavin T assay was performed. The Aβ 42 (5 μmol/L; AnaSpec, Fremont, CA, USA) peptide was incubated with test compounds (5-20 μmol/L) at 37°C for 48 hours to form aggregates. Subsequently, thioflavin T (10 μmol/L; SigmaAldrich) was added and incubated for 5 minutes, and the fluorescence intensity of samples was recorded as described. 24 The antiaggregation activity expressed as the half-maximal effective concentration (EC 50 ) was defined as the concentration of the extract or compound required for inhibiting Aβ aggregation by 50%.
| 1,1-Diphenyl-2-picrylhydrazyl assay
The free radical scavenging activity of the test compounds (10-160 µmol/L) was determined using the stable 1,1-diphenyl-2-picrylhydrazyl (DPPH, Sigma-Aldrich) free radical assay as described previously. 17 The radical scavenging activity was calculated using the following formula: [1 − (absorbance of the sample/absorbance of the control) × 100]. The antioxidant activity was expressed as EC 50 , which was defined as the concentration required for inhibiting DPPH radicals by 50%.
| Cell culture and IC 50 assay
Tet-On Aβ-GFP 293/SH-SY5Y cells 24 were maintained in Dulbecco's 
| Aβ-GFP fluorescence assay
Tet-On Aβ-GFP 293 cells were seeded in 96-well plates at a density of 8 × 10 3 cells/well. The test compounds were added the following day. After 8 hours in culture, doxycycline (2 µg/mL, Sigma-Aldrich) was added to induce Aβ-GFP expression. On day 5, the cells were Fold change was calculated using the formula 2 ΔCt , ΔC T = C T (control) − C T (target), in which C T indicates the cycle threshold. 
| ROS analysis
| Neurite outgrowth analysis
Tet-On Aβ-GFP SH-SY5Y cells were seeded at a density of 
| Acetylcholinesterase activity assay
Tet-On Aβ-GFP SH-SY5Y cells were seeded at a density of 4 × 10 5 cells/well in a 6-well plate, and retinoic acid (10 µmol/L) was added at the seeding time. On the following day, the cells were treated with the test compounds (1 µmol/L), and Aβ-GFP expression was induced as described. On day 8, the cells were collected and resuspended in PBS, followed by sonication and centrifugation at 14 000 g for 5 minutes 
Uninduced Induced + Licochalcone A (1 µM) Immunoreactive bands were detected using a chemiluminescent substrate (Millipore). 
| RNA interference
| Statistical analysis
For each set of values, data were represented as the mean of three independent experiments. Differences between groups were evaluated using two-tailed Student's t test or analysis of variance (ANOVA; one-way, and two-way) with post hoc LSD adjustment when appropriate. P values <0.05 were considered statistically significant.
| RE SULTS
| Test compounds and IC 50 cytotoxicity
The test compounds were classified into two groups: one is defined in terms of the structure of Lico A (LM-004, LM-006, and LM-026) and the other is a coumarin-chalcone hybrid (LM-016 and LM-031) generated through a ring closure reaction of chalcone ( Figure 1A ). In uninduced Aβ-GFP 293/SH-SY5Y cells, the IC 50 value of LM-031 (>100 μmol/L) was similar to that of coumarin (>100/>100 μmol/L), whereas the IC 50 value of Lico A was lower (51/47 μmol/L).
Naturally occurring coumarin and Lico
F I G U R E 4 Neuroprotective effects of test compounds on Tet-On Aβ-GFP SH-SY5Y cells. A, Experimental outline. Cells were plated
with retinoic acid (RA, 10 µmol/L). On the following day, 1 µmol/L Lico A, coumarin, LM-006, LM-026, 1-10 µmol/L LM-016, LM-031, or 5 µmol/L curcumin were added to cells for 8 hours, followed by the induction of Aβ-GFP expression (+ Dox, 2 µg/mL) for 6 days. Neurite outgrowth was assessed after TUBB3 staining. In addition, the CASP3 level and AChE activity were assessed. B, CASP3 protein level was analyzed through immunoblotting using CASP3 and GAPDH (internal control) antibodies (n = 3). To normalize, the expression level in uninduced (−Dox) cells was set at 100% The ROS scavenging activity of the test compounds was examined using the DPPH assay. Kaempferol, a natural flavonol with a strong antioxidant property, 31 was also included as a positive control. As shown in Figure 2B, 
| Effects of test compounds on Tet-On Aβ-GFP 293 cells
We examined the potential of test compounds to prevent cellular 
| Effects of test compounds on Tet-On Aβ-GFP SH-SY5Y cells
To further evaluate the neuroprotective effect of test compounds, we applied these compounds to the Tet-On Aβ-GFP SH-SY5Y cells ( Figure 4A ). 38 The In the brains of patients with AD, Aβ aggregation colocalized with AChE, which accelerated Aβ misfolding. 39 A monoclonal antibody against AChE reduced the formation of Aβ aggregation. 40 Specific inhibitors of AChE provide an attractive possibility for treating AD. 41 Thus, we assessed the potential of the test 
Enhanced expression of HSPB1, NRF2, and CREB pathways following test compound administration in Aβ-GFP SH-SY5Y cells. On day 2, differentiated SH-SY5Y cells were pretreated with 1 μmol/L LM-031, Lico A, or coumarin for 8 hours, and Aβ-GFP expression was induced for 6 days. Relative A, HSPB1 and soluble Aβ-GFP, B, NRF2, GCLC, and NQO1, and C, CREB, pCREB, BDNF, BCL2, and BAX protein levels were analyzed through immunoblotting using specific antibodies. Protein levels were normalized to β-actin or β-tubulin internal control. Relative protein levels are shown on the right side of the representative Western blot images. To normalize, the expression level in uninduced (−Dox) cells was set at 100%. For Aβ-GFP, the soluble level in induced (+Dox) cells was set at 100%. P values between induced and uninduced cells ( # P < 0.05 and ## P < 0.01) as well as between treated and untreated cells (*P < 0.05 and **P < 0.01) were compared overexpression (97%-109% vs 122%; Figure 4E ). LM-031 showed the best activity in reducing AChE activity (97% in 1 μmol/L) and thus was selected for further investigation. Aβ-induced neural stem/progenitor cell toxicity. 11 As shown in Figure 5B , the induction of Aβ-GFP for 6 days significantly attenuated the expression of NRF2 (76%), GCLC (84%), and NQO1 (75%) compared with that in uninduced control (100%). This reduction can be rescued by the addition of LM-031, Lico A, or coumarin, which significantly increased the expression of NRF2 (108%-112%), GCLC (110%-115%), and NQO1 (117%-137%) compared with that in untreated cells (76% for NRF2, 84% for GCLC, 75% for NQO1).
Accumulation of Aβ reduces CREB activation/phosphorylation, 45 which plays a central role in synaptic dysfunction and memory impairment in AD. 46 Following phosphorylation at Ser133, CREB upregulated BCL2 47 and BDNF 48 gene expression through the recruitment of the coactivator CBP to promote cell survival and modulate synaptic activity. CREB-dependent BDNF and BCL2 pathways are impaired in the hippocampus of APP transgenic mice, and the overexpression of CREB could protect against Aβ-induced neuronal apoptosis in rat primary hippocampal neurons. 49 Thus, we examined the protein levels of CREB/pCREB, BDNF, and BCL2 following treatment with LM-031, Lico A, or coumarin in Tet-On Aβ-GFP SH-SY5Y cells.
The protein expression of CREB (84%), pCREB (70%), pro-BDNF (88%), mature BDNF (93%), and BCL2 (87%) was attenuated after the induction of Aβ-GFP for 6 days relative to the control (100%, Figure 5C ).
The addition of LM-031, Lico A, or coumarin rescued the reduction of CREB (94% vs 84%), pCREB (103%-122% vs 70%), pro-BDNF (104%-110% vs 88%), mature BDNF (99%-106% vs 93%), and BCL2
(94%-107% vs 87%). In response to the antiapoptotic BCL2 change, the expression of proapoptotic BAX increased after the induction of Aβ-GFP (133% of the control), whereas addition of LM-031, Lico A, or coumarin attenuated the BAX expression level (83%-91% vs 133%).
Aβ deposition causes neuronal death through many possible mechanisms including oxidative stress, excitotoxicity, energy depletion, inflammation, and apoptosis. 50 Catalpol protected primary cultured cortical neurons induced by Aβ 42 through a mitochondrial-dependent caspase pathway. 51 Hyperbaric oxygen and a Ginkgo biloba extract (EGB761) improved escape latency in rats administered with Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] by increasing SOD and GSH expression and reducing BAX and caspase 3 expression. 52 In our study, treatment with LM-031 upregulated antioxidant NRF2 pathways and reduced BAX and CASP3 expression in 
| HSPB1, NRF2, and CREB as therapeutic targets in LM-031-treated Aβ-GFP SH-SY5Y cells
We explored the effect of silencing HSPB1, NRF2, and CREB genes on neurite outgrowth by using lentivirus-mediated RNA interference.
F I G U R E 6 HSPB1, NRF2, and CREB as therapeutic targets in LM-031-treated Aβ-GFP SH-SY5Y cells. A, Experimental outline. Aβ-GFP SH-SY5Y cells were plated into 6-well (for protein analysis) or 24-well (for outgrowth analysis) plates with retinoic acid (RA, 10 µmol/L) added on day 1. On the following day, cells were infected with lentiviruses expressing shRNA (HSPB1, NRF2, CREB-specific, or scrambled). At 24 hours postinfection, LM-031 (1 µmol/L) was added to the cells for 8 hours, followed by the induction of Aβ-GFP expression (+ Dox, 2 µg/mL) for 6 days. Then, the cells were collected for HSPB1, NRF2, or CREB protein analysis through immunoblotting (GAPDH as a loading control) and neurite outgrowth analysis through high-content analysis. B, Western blot analysis of HSPB1, NRF2, and CREB protein levels in LM-031-treated cells infected with HSPB1, NRF2, CREB-specific, or a negative control scramble shRNA. To normalize, the relative HSPB1/NRF2/CREB level of uninduced cells was set at 100%. P values: comparisons between induced vs uninduced cells, LM-031-treated vs untreated cells, or scramble vs HSPB1/NRF2/CREB shRNA-infected cells (n = 3). C, Microscopic images of uninduced or induced Aβ-GFP SH-SY5Y cells infected with scramble shRNA or LM-031 (1 μmol/L) treated cells infected with scramble or HSPB1/NRF2/CREB-specific shRNA. Nuclei were counterstained with Hoechst 33342 (blue). D, Neurite outgrowth assay, including length, process, and branch, of LM-031-treated Aβ-GFP SH-SY5Y cells infected with HSPB1/NRF2/CREB-specific or a scramble shRNA. To normalize, the relative neurite length/process/branch of scramble shRNA-infected, uninduced cells without LM-031 treatment was set at 100%. P values: comparisons between induced vs uninduced cells, LM-031-treated vs untreated cells, or scramble shRNA vs HSPB1/NRF2/CREB-specific shRNA-infected cells (n = 3)
Aβ-GFP SH-SY5Y cells were infected with HSPB1-specific, NRF2-specific, CREB-specific, or scramble (negative control) shRNA. On the following day, cells were pretreated with LM-031 for 8 hours,
followed by the induction of Aβ-GFP expression by using doxycycline for 6 days ( Figure 6A ). In scramble shRNA-infected cells, the induction of Aβ-GFP reduced the expression of HSPB1 (79%), NRF2
(56%), and CREB (77%) relative to the control (100%). Treatment with LM-031 significantly increased the expression of HSPB1 (125% vs 79%), NRF2 (136% vs 56%), and CREB (101% vs 77%), the effect of which was attenuated by HSPB1-specific (75% vs 125%), NRF2-specific (27% vs 136%), and CREB-specific (68% vs 101%) shRNA ( Figure 6B ). In line with the expression of HSPB1, NRF2, and CREB,
we observed an improvement in neurite outgrowth, including in its length (109% vs 86%), process (107% vs 87%), and branch (106% vs 73%; Figure 
